Re: Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study (European Urology, 2020)

(untitled) - Philippou, Y; Protheroe, AS; Bryant, RJ